GenSight Biologics SA 2017 IR
The report highlights GenSight Biologics' progress in developing gene therapies for severe retinal neurodegenerative diseases during 2017. Key achievements include completing enrollment for the Phase III RESCUE and REVERSE clinical trials of its lead product candidate, GS010, and receiving MHRA approval to initiate the Phase I/II PIONEER trial for GS030. The company also established its first U.S. subsidiary, GenSight Biologics Inc., and successfully raised ’22.5 million through a private placement. On the sustainability front, the company implemented greenhouse gas emission measurements for business travel and maintained strict compliance with humane animal testing standards.
Company: GenSight Biologics SA
Sector: Professional & technical services
Country: France
Year: 2017
Type: IR
Pages: 264
Back to company
GenSight Biologics SA
Registration Document
The report highlights GenSight Biologics' progress in developing gene therapies for severe retinal neurodegenerative diseases during 2017. Key achievements include completing enrollment for the Phase III RESCUE and REVERSE clinical trials of its lead product candidate, GS010, and receiving MHRA approval to initiate the Phase I/II PIONEER trial for GS030. The company also established its first U.S. subsidiary, GenSight Biologics Inc., and successfully raised ’22.5 million through a private placement. On the sustainability front, the company implemented greenhouse gas emission measurements for business travel and maintained strict compliance with humane animal testing standards.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Jan 1, 2017 - Dec 31, 2017
Fiscal Year
2017
Published
Apr 27, 2018
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women in Management
Workplace Fatalities
Employees